Comparing an Investigational Targeted Drug AZD5335 to Standard Treatments in People With Platinum‑Resistant Ovarian Cancer (TREVI‑OC‑01)
Treatment
Phase 3 treatment study for platinum-resistant ovarian cancer
Clinicaltrials.gov identifier:NCT07218809
Study Contact Information:
AstraZeneca Clinical Study Information Center
📞 1‑877‑240‑9479
📧 information.center@astrazeneca.com
About the Study
This study is testing whether a new called AZD5335 works better than currently used treatments for people with platinum‑resistant ovarian, , or primary peritoneal cancer. The study is looking at how long people live without their cancer getting worse while taking AZD5335 compared with standard treatments.
AZD5335 is a type of known as an antibody-drug conjugate (ACD). ACDs are made up of an antibody attached to chemotherapy. The antibody binds to the cancer cell and delivers the chemotherapy directly into the cell.
This study is open to people whose cancer returned or got worse after receiving a .
This Study is Open To:
People may be eligible if they have all of the following:
- Are 18 years or older.
- High‑grade ovarian cancer, cancer, or primary peritoneal cancer.
- Cancer that is platinum‑resistant (it came back within 6 months after platinum chemotherapy).
- Received 1 to 3 prior lines of treatment
- Are well enough to receive single‑agent treatment.
-
People with a known mutation must have already received a , if appropriate, unless they could not tolerate it.
This Study is NOT Open To:
People cannot participate if they have any of the following:
- The cancer is primary platinum refractory, which means it didn't respond or got worse on platinum chemotherapy.
- Active or chronic corneal (eye surface) problems.
- Have a history of serious lung inflammation (ILD or pneumonitis) or significant lung disease.
What the Study Involves
Before joining, each participant’s tumor will be tested for known as folate receptor alpha (FRα). Based on the results, participants will be placed into one of two groups.
FRα‑High Group
People whose tumor is FRα-high will be randomly assigned to one of two groups. One group will receive the investigational drug AZD5335 and the other group will receive an FDA-approved drug called Elahere (mirvetuximab soravtansine). Both drugs are a type of known as an antibody-drug conjugate (ACD). ACDs are made up of an antibody attached to chemotherapy. The antibody binds to the cancer cell and delivers the chemotherapy directly into the cell.
- AZD5335 group: People in this group will receive the investigational drug AZD5335 by intravenous (IV) injection every three weeks.
- Standard of care group: People in this group will receive the drug Elahere (mirvetuximab soravtansine) by intravenous (IV) injection every three weeks.
FRα‑Low Group
People whose tumor is FRα-high will be randomly assigned to one of two groups. One group will receive the investigational drug AZD5335 and the other group will receive standard chemotherapy.
- AZD5335 group: People in this group will receive the investigational drug AZD5335 by intravenous (IV) injection every three weeks.
- Standard chemotherapy group: People in this group will receive their doctor's choice of chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan). The frequency of treatment will depend on which chemotherapy is selected.
Treatment continues until one of the following happens:
- The cancer gets worse
- Side effects become unacceptable or unsafe
- The participant or doctor decides to stop treatment for another medical reason
- The participant chooses to stop the study treatment
All participants will be followed for several years, even after they stop the study treatment.
Study Contact Information:
AstraZeneca Clinical Study Information Center
📞 1‑877‑240‑9479
📧 information.center@astrazeneca.com
Locations:
Florida
City: Jupiter RECRUITING
Facility: Research Site
Contact Info:
No contact info provided
Ohio
City: Dayton RECRUITING
Facility: Research Site
Contact Info:
No contact info provided
Other Countries
Country: Australia
City: St Leonards RECRUITING
Facility: Research Site
Contact Info:
No contact info provided
Treatment
Phase 3 treatment study for platinum-resistant ovarian cancer
Clinicaltrials.gov identifier:NCT07218809
Study Contact Information:
AstraZeneca Clinical Study Information Center
📞 1‑877‑240‑9479
📧 information.center@astrazeneca.com